Towards better reimbursement of therapies
Most of the drugs used to treat children and adolescents with cancer are in fact only approved for adults. Therefore, health insurance companies are not obliged to cover the costs. The families concerned and the paediatric oncologists regret that the number of cases in which coverage of costs is difficult or is even refused is increasing.
In 2019, in response to a postulate of the Committee for Social Security and Health of the National Council initiated by Childhood Cancer Switzerland, the Federal Council promised to re-evaluate the situation regarding the assumption of the costs of medicines for children with cancer in order to avoid cases of unequal treatment in the future.